Stephen Shuttleworth
Directeur Technique/Scientifique/R&D chez Nalo Therapeutics, Inc.
Profil
Dr. Stephen J.
Shuttleworth is a Chief Technology Officer at Nalo Therapeutics, Inc., an Advisor at Autobahn Labs, Inc., a Venture Partner at Samsara Biocapital LLC and a Professor at The University of Manchester.
Dr. Shuttleworth was previously employed as a Non-Executive Director by Hox Therapeutics Ltd., a Chemistry Director & Oncology Program Leader by Piramed Ltd., an Associate Director by Tularik, Inc., a Principal by Amgen, Inc., a Head-New Projects Development by Cancer Research UK, a Principal by Celltech Chiroscience Plc, a Director, COO & Chief Scientific Officer by Karus Therapeutics Ltd., and a Principal by Shire Canada, Inc. He received his undergraduate degree from The University of Liverpool and a doctorate degree from The University of Liverpool.
Postes actifs de Stephen Shuttleworth
| Sociétés | Poste | Début |
|---|---|---|
| The University of Manchester | Corporate Officer/Principal | 01/01/2014 |
Samsara Biocapital LLC
 Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Private Equity Investor | 01/01/2019 |
Nalo Therapeutics, Inc.
 Nalo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nalo Therapeutics, Inc. is a company that focuses on developing therapeutics to address unmet needs in cancer. Nalo Therapeutics is based in Belmont, CA and the CEO of the company is Keith Wilson. The company targets oncogenic driver mutations and/or proteins that are often difficult to drug. The company was founded in 2017 and collaborates with UCSF scientific cofounders. | Directeur Technique/Scientifique/R&D | 01/10/2019 |
Autobahn Labs, Inc.
 Autobahn Labs, Inc. Medical/Nursing ServicesHealth Services Autobahn Labs, Inc. is a virtual incubator that partners with research institutions to accelerate the advancement of early-stage drug discovery and development. The company is based in Palo Alto, CA. The organization invests intellectual, financial, and physical capital to efficiently move projects from feasibility to novel drug candidates. Autobahn Labs was created by Samsara Biocapital, Evotec, and KCK Ltd. | Consultant / Advisor | 01/01/2019 |
Anciens postes connus de Stephen Shuttleworth
| Sociétés | Poste | Fin |
|---|---|---|
Karus Therapeutics Ltd.
 Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Directeur Technique/Scientifique/R&D | 01/01/2020 |
Piramed Ltd.
 Piramed Ltd. Miscellaneous Commercial ServicesCommercial Services PIramed Ltd. develops drugs, diagnostics, and other therapeutic products. It develops treatment for cancers which include proliferation, invasion, angiogenesis, and metastasis. The company was co-founded by Michael Waterfield, Peter Parker, and Paul Workman in 2003 and is headquartered in Slough, UK. | Corporate Officer/Principal | 01/01/2006 |
Tularik, Inc.
 Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/01/2003 |
Hox Therapeutics Ltd.
 Hox Therapeutics Ltd. BiotechnologyHealth Technology Hox Therapeutics Ltd. develops therapeutics for cancer diseases based on the role of HOX genes. The private company is based in Guildford, UK. | Directeur/Membre du Conseil | - |
Shire Canada, Inc.
 Shire Canada, Inc. Pharmaceuticals: MajorHealth Technology Shire Canada, Inc. develops and markets medicines. It focuses on attention deficit hyperactivity disorder (ADHD), rare diseases, as well as gastrointestinal and renal diseases. The firm develops treatments for genetic disorders known as rare or orphan diseases. The company was founded in 1986 and is headquartered in Saint-Laurent, Canada. | Corporate Officer/Principal | - |
Formation de Stephen Shuttleworth
| The University of Liverpool | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AMGEN INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Celltech Chiroscience Plc
 Celltech Chiroscience Plc Miscellaneous Commercial ServicesCommercial Services Part of UCB SA, Celltech Chiroscience Plc is a research-based pharmaceutical group. | Commercial Services |
Piramed Ltd.
Piramed Ltd. Miscellaneous Commercial ServicesCommercial Services PIramed Ltd. develops drugs, diagnostics, and other therapeutic products. It develops treatment for cancers which include proliferation, invasion, angiogenesis, and metastasis. The company was co-founded by Michael Waterfield, Peter Parker, and Paul Workman in 2003 and is headquartered in Slough, UK. | Commercial Services |
Cancer Research UK
 Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom. | Commercial Services |
Shire Canada, Inc.
Shire Canada, Inc. Pharmaceuticals: MajorHealth Technology Shire Canada, Inc. develops and markets medicines. It focuses on attention deficit hyperactivity disorder (ADHD), rare diseases, as well as gastrointestinal and renal diseases. The firm develops treatments for genetic disorders known as rare or orphan diseases. The company was founded in 1986 and is headquartered in Saint-Laurent, Canada. | Health Technology |
Hox Therapeutics Ltd.
Hox Therapeutics Ltd. BiotechnologyHealth Technology Hox Therapeutics Ltd. develops therapeutics for cancer diseases based on the role of HOX genes. The private company is based in Guildford, UK. | Health Technology |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Finance |
Nalo Therapeutics, Inc.
Nalo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nalo Therapeutics, Inc. is a company that focuses on developing therapeutics to address unmet needs in cancer. Nalo Therapeutics is based in Belmont, CA and the CEO of the company is Keith Wilson. The company targets oncogenic driver mutations and/or proteins that are often difficult to drug. The company was founded in 2017 and collaborates with UCSF scientific cofounders. | Health Technology |
Autobahn Labs, Inc.
Autobahn Labs, Inc. Medical/Nursing ServicesHealth Services Autobahn Labs, Inc. is a virtual incubator that partners with research institutions to accelerate the advancement of early-stage drug discovery and development. The company is based in Palo Alto, CA. The organization invests intellectual, financial, and physical capital to efficiently move projects from feasibility to novel drug candidates. Autobahn Labs was created by Samsara Biocapital, Evotec, and KCK Ltd. | Health Services |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Commercial Services |
